Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
ViroMissile, Inc.
Arcus Biosciences, Inc.
Seagen Inc.
Tizona Therapeutics, Inc
Genentech, Inc.
National Institutes of Health Clinical Center (CC)
BioNTech SE
NiKang Therapeutics, Inc.
Poseida Therapeutics, Inc.
MacroGenics
SN BioScience
Cue Biopharma
MOMA Therapeutics
Innate Pharma
M.D. Anderson Cancer Center
GlaxoSmithKline
Blueprint Medicines Corporation
HiFiBiO Therapeutics
SystImmune Inc.
Rondo Therapeutics
Actym Therapeutics, Inc.
NiKang Therapeutics, Inc.
Nurix Therapeutics, Inc.
Pfizer
Arcus Biosciences, Inc.
GONGCHU Biotechnology Co., Ltd
Exelixis
Jonsson Comprehensive Cancer Center
First Affiliated Hospital of Zhejiang University
Toray Industries, Inc
University of Virginia
University Hospital, Ghent
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Monopar Therapeutics
Monopar Therapeutics
Rutgers, The State University of New Jersey
ImmVirx Pty Ltd
Seagen Inc.
Seagen Inc.
Seagen Inc.
Immatics US, Inc.
Zymeworks BC Inc.
Sotio Biotech Inc.
Carisma Therapeutics Inc
Symphogen A/S
Acepodia Biotech, Inc.
Jazz Pharmaceuticals
Vincerx Pharma, Inc.